Drugs / Human Tetanus Immunoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06635798 Comparator | Sep → Dec 2024 overdue | tetanus | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Tetanus Immunoglobulin | “The HTIG is a Chinese licensed Human Tetanus Immunoglobulin produced by Tonglu-Bio, which are derived from human plasma, and then purified and filled in the injectable vial form.” NCT06635798 ↗ |
| Known as | HTIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06635798 ↗ |
| Modality | Protein / enzyme biologic | “The HTIG is a Chinese licensed Human Tetanus Immunoglobulin produced by Tonglu-Bio, which are derived from human plasma, and then purified and filled in the injectable vial form.” NCT06635798 ↗ |
| Route | Intramuscular | “single IM gluteal injection of HTIG” NCT06635798 ↗ |